Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Non Operating Income (2016 - 2025)

KalVista Pharmaceuticals' Other Non Operating Income history spans 11 years, with the latest figure at $5.2 million for Q2 2025.

  • For Q2 2025, Other Non Operating Income rose 114.39% year-over-year to $5.2 million; the TTM value through Apr 2025 reached $8.2 million, up 5.12%, while the annual FY2025 figure was $4.8 million, 50.73% down from the prior year.
  • Other Non Operating Income for Q2 2025 was $5.2 million at KalVista Pharmaceuticals, up from -$985000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $5.2 million in Q2 2025 and bottomed at -$985000.0 in Q4 2024.
  • The 4-year median for Other Non Operating Income is $2.2 million (2021), against an average of $2.0 million.
  • The largest annual shift saw Other Non Operating Income soared 1484.67% in 2021 before it crashed 137.61% in 2024.
  • A 4-year view of Other Non Operating Income shows it stood at $2.2 million in 2021, then rose by 20.64% to $2.6 million in 2023, then plummeted by 137.61% to -$985000.0 in 2024, then surged by 629.34% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Other Non Operating Income are $5.2 million (Q2 2025), -$985000.0 (Q4 2024), and $1.6 million (Q3 2024).